首页> 外文期刊>Platelets >Platelet extracellular vesicles as biomarkers for arterial thrombosis
【24h】

Platelet extracellular vesicles as biomarkers for arterial thrombosis

机译:血小板细胞外囊泡作为动脉血栓形成的生物标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Arterial thrombosis is a major and global cause of human death and disability. Considering the socioeconomic costs of arterial thrombosis, identification of biomarkers to predict and detect arterial thrombosis at an early stage is an important public health goal. Platelet extracellular vesicles (PEV) are a new candidate biomarker of arterial thrombosis. PEV can be measured in biorepositories, thereby offering the possibility to validate PEV in multicenter clinical trials. PEV analysis has been hitherto hampered by lack of standardized methodology, but substantial technological improvements of PEV detection techniques have been achieved recently. However, before PEV emerge from research tools to clinical applications, a number of issues should be clarified. To facilitate validation of PEV as biomarkers of thrombosis, we discuss (i) whether PEV are useful as biomarkers of thrombosis, (ii) why previous conclusions on PEV concentrations, composition and functions require re-evaluation, and (iii) which questions have to be answered before PEV become clinically useful.
机译:动脉血栓形成是导致人类死亡和残疾的主要全球原因。考虑到动脉血栓形成的社会经济成本,识别早期预测和检测动脉血栓形成的生物标志物是一个重要的公共卫生目标。血小板胞外小泡(PEV)是动脉血栓形成的一个新的候选生物标志物。可以在生物库中测量PEV,从而为在多中心临床试验中验证PEV提供了可能性。迄今为止,由于缺乏标准化方法,PEV分析一直受到阻碍,但最近,PEV检测技术取得了实质性的技术进步。然而,在PEV从研究工具发展到临床应用之前,有一些问题需要澄清。为了促进PEV作为血栓生物标志物的验证,我们讨论(i)PEV作为血栓生物标志物是否有用,(ii)为什么之前关于PEV浓度、成分和功能的结论需要重新评估,以及(iii)在PEV成为临床有用之前必须回答哪些问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号